Pharmacodynamic aspects of peptide administration biological response modifiers

Research output: Contribution to journalReview article

32 Citations (Scopus)

Abstract

Cytokines, growth factors and other recombinant proteins have been one of the most rapidly growing areas of pharmaceuticals. Further, the development of these bio-engineered drugs is occurring at an astonishing pace with rapid preclinical and clinical development and licensing by regulatory agencies. In addition, the availability of the gene sequences and rational drug design technologies have resulted in a rapid development of engineered genes, proteins and peptidomimetics. In contrast to traditional pharmacophores, which are developed based on the identification of the maximum tolerated dose (MTD), most recombinant proteins have abnormal biodistributions, and pharmacodynamic and pharmacokinetic attributes. Within this chapter, representative cytokines including interferon-alpha (IFN-α), IFN-γ and interleukin-2 are used to discuss the pharmacodynamic aspects of protein/peptide administration that are important in the development of these drugs. This includes the conceptual need for chronic immunoaugmentation for optimal therapeutic activity; the need to consider the pharmacokinetics of administration to optimize drug delivery and the nonlinear dose response relationship, which can result in a bell shaped dose response. Furthermore, these therapeutics have maximal potential in an adjuvant protocol and their development in combination with high-dose chemotherapy and stem cell rescue is discussed. The strategies for combination chemotherapy and immunotherapy, while holding great promise, require close attention to the pharmacodynamics of protein administration in order to impact on failure free and overall survival. Copyright (C) 1998 Elsevier Science B.V.

Original languageEnglish (US)
Pages (from-to)241-252
Number of pages12
JournalAdvanced Drug Delivery Reviews
Volume33
Issue number3
DOIs
StatePublished - Sep 7 1998

Fingerprint

Immunologic Factors
Interferon-alpha
Peptides
Recombinant Proteins
Pharmaceutical Preparations
Pharmacokinetics
Cytokines
Peptidomimetics
Proteins
Maximum Tolerated Dose
Drug Design
Licensure
Combination Drug Therapy
Immunotherapy
Interleukin-2
Intercellular Signaling Peptides and Proteins
Stem Cells
Technology
Drug Therapy
Therapeutics

Keywords

  • Chemotherapy
  • Cytokine
  • Dose-response
  • Immunotherapy
  • Interferon
  • Peptide
  • Pharmacodynamics
  • Recombinant proteins

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Pharmacodynamic aspects of peptide administration biological response modifiers. / Talmadge, James E.

In: Advanced Drug Delivery Reviews, Vol. 33, No. 3, 07.09.1998, p. 241-252.

Research output: Contribution to journalReview article

@article{dcf3076c09dd4445bdcdcc45e2f84331,
title = "Pharmacodynamic aspects of peptide administration biological response modifiers",
abstract = "Cytokines, growth factors and other recombinant proteins have been one of the most rapidly growing areas of pharmaceuticals. Further, the development of these bio-engineered drugs is occurring at an astonishing pace with rapid preclinical and clinical development and licensing by regulatory agencies. In addition, the availability of the gene sequences and rational drug design technologies have resulted in a rapid development of engineered genes, proteins and peptidomimetics. In contrast to traditional pharmacophores, which are developed based on the identification of the maximum tolerated dose (MTD), most recombinant proteins have abnormal biodistributions, and pharmacodynamic and pharmacokinetic attributes. Within this chapter, representative cytokines including interferon-alpha (IFN-α), IFN-γ and interleukin-2 are used to discuss the pharmacodynamic aspects of protein/peptide administration that are important in the development of these drugs. This includes the conceptual need for chronic immunoaugmentation for optimal therapeutic activity; the need to consider the pharmacokinetics of administration to optimize drug delivery and the nonlinear dose response relationship, which can result in a bell shaped dose response. Furthermore, these therapeutics have maximal potential in an adjuvant protocol and their development in combination with high-dose chemotherapy and stem cell rescue is discussed. The strategies for combination chemotherapy and immunotherapy, while holding great promise, require close attention to the pharmacodynamics of protein administration in order to impact on failure free and overall survival. Copyright (C) 1998 Elsevier Science B.V.",
keywords = "Chemotherapy, Cytokine, Dose-response, Immunotherapy, Interferon, Peptide, Pharmacodynamics, Recombinant proteins",
author = "Talmadge, {James E}",
year = "1998",
month = "9",
day = "7",
doi = "10.1016/S0169-409X(98)00032-5",
language = "English (US)",
volume = "33",
pages = "241--252",
journal = "Advanced Drug Delivery Reviews",
issn = "0169-409X",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Pharmacodynamic aspects of peptide administration biological response modifiers

AU - Talmadge, James E

PY - 1998/9/7

Y1 - 1998/9/7

N2 - Cytokines, growth factors and other recombinant proteins have been one of the most rapidly growing areas of pharmaceuticals. Further, the development of these bio-engineered drugs is occurring at an astonishing pace with rapid preclinical and clinical development and licensing by regulatory agencies. In addition, the availability of the gene sequences and rational drug design technologies have resulted in a rapid development of engineered genes, proteins and peptidomimetics. In contrast to traditional pharmacophores, which are developed based on the identification of the maximum tolerated dose (MTD), most recombinant proteins have abnormal biodistributions, and pharmacodynamic and pharmacokinetic attributes. Within this chapter, representative cytokines including interferon-alpha (IFN-α), IFN-γ and interleukin-2 are used to discuss the pharmacodynamic aspects of protein/peptide administration that are important in the development of these drugs. This includes the conceptual need for chronic immunoaugmentation for optimal therapeutic activity; the need to consider the pharmacokinetics of administration to optimize drug delivery and the nonlinear dose response relationship, which can result in a bell shaped dose response. Furthermore, these therapeutics have maximal potential in an adjuvant protocol and their development in combination with high-dose chemotherapy and stem cell rescue is discussed. The strategies for combination chemotherapy and immunotherapy, while holding great promise, require close attention to the pharmacodynamics of protein administration in order to impact on failure free and overall survival. Copyright (C) 1998 Elsevier Science B.V.

AB - Cytokines, growth factors and other recombinant proteins have been one of the most rapidly growing areas of pharmaceuticals. Further, the development of these bio-engineered drugs is occurring at an astonishing pace with rapid preclinical and clinical development and licensing by regulatory agencies. In addition, the availability of the gene sequences and rational drug design technologies have resulted in a rapid development of engineered genes, proteins and peptidomimetics. In contrast to traditional pharmacophores, which are developed based on the identification of the maximum tolerated dose (MTD), most recombinant proteins have abnormal biodistributions, and pharmacodynamic and pharmacokinetic attributes. Within this chapter, representative cytokines including interferon-alpha (IFN-α), IFN-γ and interleukin-2 are used to discuss the pharmacodynamic aspects of protein/peptide administration that are important in the development of these drugs. This includes the conceptual need for chronic immunoaugmentation for optimal therapeutic activity; the need to consider the pharmacokinetics of administration to optimize drug delivery and the nonlinear dose response relationship, which can result in a bell shaped dose response. Furthermore, these therapeutics have maximal potential in an adjuvant protocol and their development in combination with high-dose chemotherapy and stem cell rescue is discussed. The strategies for combination chemotherapy and immunotherapy, while holding great promise, require close attention to the pharmacodynamics of protein administration in order to impact on failure free and overall survival. Copyright (C) 1998 Elsevier Science B.V.

KW - Chemotherapy

KW - Cytokine

KW - Dose-response

KW - Immunotherapy

KW - Interferon

KW - Peptide

KW - Pharmacodynamics

KW - Recombinant proteins

UR - http://www.scopus.com/inward/record.url?scp=0032494119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032494119&partnerID=8YFLogxK

U2 - 10.1016/S0169-409X(98)00032-5

DO - 10.1016/S0169-409X(98)00032-5

M3 - Review article

AN - SCOPUS:0032494119

VL - 33

SP - 241

EP - 252

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

IS - 3

ER -